Accelerating antibody-drug conjugate (ADC) development

Antibody–drug conjugates (ADCs) are increasingly important in oncology and other complex diseases, but their hybrid structure creates challenging pharmacokinetics and immunogenicity profiles that demand multi‑analyte evaluation across development. Traditional plate‑based ligand‑binding assays often struggle with sensitivity, throughput, and matrix interference, creating bottlenecks for high‑demand environments such as CROs.

Explore the key analytical challenges in ADC bioanalysis and how automated immunoassay platforms can enhance efficiency and reproducibility. Discover how Gyrolab^® technology performed in two case studies, delivering high‑sensitivity, low‑volume PK and immunogenicity assays that support complex, high‑throughput studies under real‑world conditions.